*** Welcome to piglix ***

Peanut butter test


The peanut butter test is a diagnostic test which aims to detect Alzheimer's disease by measuring subjects' ability to smell peanut butter through each nostril. The test was originally reported in October 2013 by researchers from the University of Florida's McKnight Brain Institute, led by professor Kenneth Heilman, and involves measuring the ability of patients to smell peanut butter held close to their nose. The researchers concluded that patients with Alzheimer's were not able to smell the peanut butter as well through their left nostril as their right one. The study's lead author, graduate student Jennifer Stamps, got the idea for the study when, while studying under Professor Heilman, she noticed that none of his patients had been tested for their sense of smell. The idea of using peanut butter came to Stamps when she administered it to patients as part of a routine test of cranial nerve function. Their decision to use it was also motivated by the fact that it is a pure odorant (i.e. is only detected by the olfactory nerve), and that Heilman had told Stamps, "If you can come up with something quick and inexpensive, we can do it."

Stamps had concluded, from her own research, that the sense of smell is dependent upon the olfactory nerve, and also noted that this nerve is one of the first things to be affected by cognitive decline. Likewise, the front part of the temporal lobe has not only been implicated in olfaction, but is also known to be one of the first areas of the brain to degenerate due to Alzheimer's. The researchers also expected the difference to be in the left nostril because in Alzheimer's, the left side of the brain is usually affected first, and because the sense of olfaction is ipsilateral—that is, the side of the body that picks up the odor is the same as the side of the brain that processes it.

Stamps cautioned that they can currently only use the test to confirm already-established diagnoses, but added that "...we plan to study patients with mild cognitive impairment to see if this test might be used to predict which patients are going to get Alzheimer's disease." NPR also reported that the study, at 94 patients, was "too small to be conclusive." In 2012, a systematic review had found that while there may be "an association between decreased olfaction and AD," "rigorously designed longitudinal cohort studies are necessary to clarify the value of olfactory identification testing in predicting the onset of AD." Ivan Oransky, global editorial director of MedPage Today, also criticized the media's favorable coverage of the study, noting that the journal in which it was published, the Journal of the Neurological Sciences, "is ranked in the bottom third of neuroscience journals by Thomson Scientific's impact factor, 162 out of 252." He also asked three other Alzheimer's researchers—Richard Caselli, Sam Gandy, and George Bartzokis—what they thought about the proposed test, and their responses were less than enthusiastic. For example, Bartzokis said, "The principal problem with smell tests is that they are nonspecific and therefore only one small piece of the diagnostic puzzle."


...
Wikipedia

...